

H-P Hartung

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2689009/h-p-hartung-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

295
papers

30,281
citations

59
h-index

172
g-index

316
ext. papers

35,330
ext. citations

8.9
avg, IF

6.77
L-index

#	Paper	IF	Citations
295	Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. <i>Annals of Neurology</i> , 2001 , 50, 121-7	9.4	5368
294	Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". <i>Annals of Neurology</i> , 2005 , 58, 840-6	9.4	4020
293	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. <i>Nature</i> , 2011 , 476, 214-9	50.4	1948
292	Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , 2010 , 362, 402-15	59.2	1686
291	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. <i>Lancet, The</i> , 2001 , 357, 1576-82	40	884
290	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017 , 376, 209-220	59.2	880
289	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017 , 376, 221-234	59.2	858
288	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2012 , 380, 1819-28	40	834
287	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2012 , 380, 1829-39	40	827
286	Guillain-Barré syndrome. <i>New England Journal of Medicine</i> , 2012 , 366, 2294-304	59.2	827
285	Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. <i>Lancet, The</i> , 2002 , 360, 2018-25	40	728
284	Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. <i>Neurology</i> , 2006 , 67, 1242-9	6.5	601
283	Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. <i>Lancet Neurology, The</i> , 2008 , 7, 136-44	24.1	505
282	Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2009 , 374, 1503-11	40	475
281	Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. <i>Lancet, The</i> , 2007 , 370, 389-97	40	417
280	Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. <i>Lancet Neurology, The</i> , 2009 , 8, 987-97	24.1	279
279	Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2016 , 387, 1075-1084	40	271

278	Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. <i>Neurology</i> , 2005 , 64, 1336-43	6.5	250
277	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. <i>Lancet, The</i> , 2019 , 394, 1352-1363	4.0	247
276	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , 2016 , 79, 206-16	9.4	219
275	Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. <i>Lancet Neurology, The</i> , 2014 , 13, 353-63	24.1	212
274	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1013-24	5	181
273	Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. <i>Neurology</i> , 2017 , 89, 1117-1126	6.5	175
272	Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015 , 72, 756-63	17.2	163
271	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1005-15	5.5	157
270	Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. <i>Lancet Neurology, The</i> , 2014 , 13, 257-67	24.1	156
269	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology, The</i> , 2018 , 17, 405-415	24.1	150
268	Disease-modifying therapies and infectious risks in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2016 , 12, 217-33	15	148
267	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology, The</i> , 2018 , 17, 35-46	24.1	146
266	Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. <i>Neurology</i> , 2017 , 89, 1107-1116	6.5	139
265	Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. <i>Neurology</i> , 2002 , 59, 909-13	6.5	136
264	Human Endogenous Retroviruses in Neurological Diseases. <i>Trends in Molecular Medicine</i> , 2018 , 24, 379-394	14.5	127
263	Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018 , 5, e504	9.1	111
262	Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 468-75	5.5	109
261	The role of interferon-gamma in the pathogenesis of experimental autoimmune disease of the peripheral nervous system. <i>Annals of Neurology</i> , 1990 , 27, 247-57	9.4	103

260	Atacept: targeting B cells in multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2010 , 3, 205-16	6.6	100
259	Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. <i>Archives of Neurology</i> , 2005 , 62, 1620-3		99
258	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <i>Lancet Neurology</i> , 2019 , 18, 1021-1033	24.1	98
257	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <i>Lancet Neurology</i> , 2019 , 18, 1009-1020	24.1	96
256	ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. <i>European Journal of Neurology</i> , 2018 , 25, 215-237	6	96
255	Regional variation of Guillain-Barré syndrome. <i>Brain</i> , 2018 , 141, 2866-2877	11.2	96
254	Advances in the understanding of the mechanism of action of IVIg. <i>Journal of Neurology</i> , 2008 , 255 Suppl 3, 3-6	5.5	92
253	Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. <i>JAMA Neurology</i> , 2015 , 72, 1458-65	17.2	90
252	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 639-647	5.5	88
251	Substance P and astrocytes: stimulation of the cyclooxygenase pathway of arachidonic acid metabolism. <i>FASEB Journal</i> , 1988 , 2, 48-51	0.9	87
250	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1386-1396	5	83
249	Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. <i>Trends in Molecular Medicine</i> , 2020 , 26, 296-310	11.5	82
248	Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 22-34	5	78
247	The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. <i>Neurology</i> , 2016 , 87, 978-875		78
246	Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. <i>Clinical Immunology</i> , 2012 , 142, 15-24	9	76
245	Immune mechanisms in inflammatory polyneuropathy. <i>Annals of the New York Academy of Sciences</i> , 1988 , 540, 122-61	6.5	76
244	Suppression of experimental autoimmune neuritis by the oxygen radical scavengers superoxide dismutase and catalase. <i>Annals of Neurology</i> , 1988 , 23, 453-60	9.4	74
243	Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1074-83	5	72

242	Macrophage-derived osteopontin induces reactive astrocyte polarization and promotes re-establishment of the blood brain barrier after ischemic stroke. <i>Glia</i> , 2015 , 63, 2198-207	9	70
241	Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. <i>JAMA Neurology</i> , 2016 , 73, 1089-98	17.2	67
240	The blood-nerve barrier in Wallerian degeneration: a sequential long-term study. <i>Muscle and Nerve</i> , 1989 , 12, 627-35	3.4	65
239	Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. Studies on PGE, TXB2 and O2- production, spreading, and the influence of calmodulin-inhibitor W-7. <i>FEBS Letters</i> , 1983 , 160, 209-12	3.8	65
238	Pushing Forward: Remyelination as the New Frontier in CNS Diseases. <i>Trends in Neurosciences</i> , 2016 , 39, 246-263	13.3	64
237	Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 43-55	5.3	59
236	Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 1183-9	5.5	59
235	Vaccination against infection in patients with multiple sclerosis. <i>Nature Reviews Neurology</i> , 2012 , 8, 143-54	5.4	58
234	Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. <i>Journal of Neurology</i> , 2008 , 255, 480-7	5.5	58
233	The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 94-105	5	56
232	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , 2019 , 18, 845-856	24.1	56
231	International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. <i>Journal of the Peripheral Nervous System</i> , 2017 , 22, 68-76	4.7	55
230	High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. <i>Neurology</i> , 2019 , 92, e48-e54	6.5	55
229	Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation. <i>Journal of Neuroinflammation</i> , 2016 , 13, 48	10.1	53
228	CIDP and other inflammatory neuropathies in diabetes - diagnosis and management. <i>Nature Reviews Neurology</i> , 2017 , 13, 599-611	15	53
227	Impact of HMG-CoA reductase inhibition on brain pathology. <i>Trends in Pharmacological Sciences</i> , 2007 , 28, 342-9	13.2	52
226	Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 862-72	5	51
225	Sodium intake and multiple sclerosis activity and progression in BENEFIT. <i>Annals of Neurology</i> , 2017 , 82, 20-29	9.4	50

224	Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1036-44	5	50
223	The cyclin-dependent kinase inhibitor p57kip2 is a negative regulator of Schwann cell differentiation and in vitro myelination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 8748-53	11.5	50
222	Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. <i>Current Opinion in Neurology</i> , 2019 , 32, 365-377	7.1	50
221	Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1466-71	5	47
220	Immune-mediated neuropathies. <i>Nature Reviews Disease Primers</i> , 2018 , 4, 31	51.1	47
219	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1605-1617	5	46
218	pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 15216-15225	11.5	45
217	Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. <i>Journal of Neurology</i> , 2007 , 254, 827-37	5.5	45
216	Macrophages but not Schwann cells express Ia antigen in experimental autoimmune neuritis. <i>Annals of Neurology</i> , 1990 , 28, 70-7	9.4	44
215	Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. <i>Neurology</i> , 2017 , 89, 1584-1593	6.5	42
214	Subtle retinal pathology in amyotrophic lateral sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2014 , 1, 290-7	5.3	41
213	Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography. <i>Neurology</i> , 2015 , 85, 610-8	6.5	40
212	A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 885-93	5	40
211	No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. <i>Neurology</i> , 2015 , 85, 1694-701	6.5	39
210	The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1200-3	5	38
209	Pathogenesis and treatment of immune-mediated neuropathies. <i>Therapeutic Advances in Neurological Disorders</i> , 2009 , 2, 261-81	6.6	38
208	Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , 2020 , 19, 998-1009	24.1	38
207	Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. <i>Neurology</i> , 2016 , 87, 1985-1992	6.5	38

206	Role of B Cells in Multiple Sclerosis and Related Disorders. <i>Annals of Neurology</i> , 2021 , 89, 13-23	9.4	38
205	Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis. <i>Neurotherapeutics</i> , 2016 , 13, 47-57	6.4	36
204	Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension. <i>Journal of Neurology</i> , 2017 , 264, 1370-1380	5.5	36
203	Alemtuzumab: the advantages and challenges of a novel therapy in MS. <i>Neurology</i> , 2014 , 83, 87-97	6.5	35
202	CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 151-6	5	35
201	Fingolimod induces the transition to a nerve regeneration promoting Schwann cell phenotype. <i>Experimental Neurology</i> , 2015 , 271, 25-35	5.7	34
200	Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. <i>Lancet Neurology</i> , 2018 , 17, 689-698	24.1	34
199	The Molecular Basis for Remyelination Failure in Multiple Sclerosis. <i>Cells</i> , 2019 , 8,	7.9	34
198	A phase IIa randomized clinical study testing GNBAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up. <i>Journal of Neuroimmunology</i> , 2015 , 285, 68-70	3.5	33
197	Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis. <i>Drugs</i> , 2017 , 77, 1755-1768	12.1	33
196	Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2019 , 32, 305-312	7.1	33
195	Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. <i>Journal of Neurology</i> , 2016 , 263, 1418-26	5.5	32
194	Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: update on current trials and perspectives. <i>Current Opinion in Neurology</i> , 2016 , 29, 199-204	7.1	31
193	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. <i>EBioMedicine</i> , 2020 , 56, 102807	8.8	30
192	Development of oral cladribine for the treatment of multiple sclerosis. <i>Journal of Neurology</i> , 2010 , 257, 163-70	5.5	30
191	Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis. <i>Neurology</i> , 2020 , 94, e2373-e2383	6.5	30
190	Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study. <i>Journal of Neurology</i> , 2016 , 263, 1626-32	5.5	29
189	Substance P, the immune system and inflammation. <i>International Reviews of Immunology</i> , 1989 , 4, 229-49.6	4.6	29

188	Oligodendroglial maturation is dependent on intracellular protein shuttling. <i>Journal of Neuroscience</i> , 2015 , 35, 906-19	6.6	28
187	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , 2020 , 19, 988-997	24.1	28
186	PML: The Dark Side of Immunotherapy in Multiple Sclerosis. <i>Trends in Pharmacological Sciences</i> , 2015 , 36, 799-801	13.2	27
185	Genome-wide significant association with seven novel multiple sclerosis risk loci. <i>Journal of Medical Genetics</i> , 2015 , 52, 848-55	5.8	27
184	Chemically modified low density lipoproteins as inducers of enzyme release from macrophages. <i>FEBS Letters</i> , 1985 , 186, 211-4	3.8	27
183	Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. <i>PLoS ONE</i> , 2017 , 12, e0170395	3.7	27
182	Iron-sulfur glutaredoxin 2 protects oligodendrocytes against damage induced by nitric oxide release from activated microglia. <i>Glia</i> , 2017 , 65, 1521-1534	9	26
181	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. <i>Journal of Neurology</i> , 2021 , 268, 3961-3968	5.5	26
180	Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model. <i>Journal of Neuroinflammation</i> , 2018 , 15, 71	10.1	24
179	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1255-1262	5	24
178	IVIg regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). <i>Journal of Neuroimmunology</i> , 2014 , 274, 225-9	3.5	24
177	Redox-regulated fate of neural stem progenitor cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2015 , 1850, 1543-54	4	24
176	Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors. <i>Archives of Neurology</i> , 2011 , 68, 1428-31		24
175	Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6, e590	9.1	23
174	Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1273-1288	5	23
173	Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. <i>Neurology</i> , 2020 , 94, e407-e418	6.5	23
172	COVID-19 and management of neuroimmunological disorders. <i>Nature Reviews Neurology</i> , 2020 , 16, 347-348		23
171	Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 113-121	5.5	23

170	Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. <i>Neurology</i> , 2019 , 93, e1778-e1786	6.5	22
169	Hyperglycemia and PPAR γ Antagonistically Influence Macrophage Polarization and Infarct Healing After Ischemic Stroke. <i>Stroke</i> , 2015 , 46, 2935-42	6.7	22
168	Immune regulation of multiple sclerosis. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2014 , 122, 3-14	3	22
167	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. <i>Brain</i> , 2020 , 143, 2637-2652	11.2	22
166	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β 1a in MS. <i>Neurology</i> , 2016 , 87, 1464-1472	6.5	21
165	Risk evaluation and monitoring in multiple sclerosis therapeutics. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1306-11	5	21
164	Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria. <i>Lancet Neurology</i> , 2011 , 10, 293-5	24.1	21
163	Downregulation of monocytic differentiation via modulation of CD147 by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. <i>PLoS ONE</i> , 2017 , 12, e0189701	3.7	21
162	Teriflunomide promotes oligodendroglial differentiation and myelination. <i>Journal of Neuroinflammation</i> , 2018 , 15, 76	10.1	20
161	Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia. <i>Neurology</i> , 2014 , 83, 2153-7	6.5	20
160	Endovascular Thrombectomy as a Means to Improve Survival in Acute Ischemic Stroke: A Meta-analysis. <i>JAMA Neurology</i> , 2019 , 76, 850-854	17.2	19
159	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018 , 4, 2055217318760642	2	19
158	Outcome and Treatment Effects in Stroke Associated with Acute Cervical ICA Occlusion. <i>PLoS ONE</i> , 2017 , 12, e0170247	3.7	19
157	APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. <i>Neurology</i> , 2021 , 97, 68-79	6.5	19
156	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. <i>Trials</i> , 2016 , 17, 345	2.8	19
155	Clinical presentation of Moyamoya angiopathy in Europeans: experiences from Germany with 200 patients. <i>Journal of Neurology</i> , 2019 , 266, 1421-1428	5.5	18
154	Misdiagnoses and delay of diagnoses in Moyamoya angiopathy-a large Caucasian case series. <i>Journal of Neurology</i> , 2019 , 266, 1153-1159	5.5	18
153	Retinal pathology in idiopathic moyamoya angiopathy detected by optical coherence tomography. <i>Neurology</i> , 2015 , 85, 521-7	6.5	18

152	Safety of bridging antiplatelet therapy with the gpIIb-IIIa inhibitor tirofiban after emergency stenting in stroke. <i>PLoS ONE</i> , 2017 , 12, e0190218	3.7	18
151	Nimodipine confers clinical improvement in two models of experimental autoimmune encephalomyelitis. <i>Journal of Neurochemistry</i> , 2018 , 146, 86	6	18
150	Human mesenchymal factors induce rat hippocampal- and human neural stem cell dependent oligodendrogenesis. <i>Glia</i> , 2018 , 66, 145-160	9	18
149	High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 291-309	4	18
148	Efficacy of STA-MCA bypass surgery in moyamoya angiopathy: long-term follow-up of the Caucasian Krupp Hospital cohort with 81 procedures. <i>Journal of Neurology</i> , 2018 , 265, 2425-2433	5.5	18
147	The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017 , 3, 2055217317732802	2	17
146	Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy. <i>Journal of Neuroinflammation</i> , 2016 , 13, 278	10.1	17
145	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	17
144	Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 - continuity and change. <i>Current Opinion in Neurology</i> , 2019 , 32, 327-337	7.1	17
143	Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. <i>Brain</i> , 2020 , 143, 1127-1142	11.2	17
142	Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling. <i>Journal of Neuroinflammation</i> , 2016 , 13, 143	10.1	16
141	Remyelination in multiple sclerosis: from concept to clinical trials. <i>Current Opinion in Neurology</i> , 2019 , 32, 378-384	7.1	16
140	Secretome analysis of nerve repair mediating Schwann cells reveals Smad-dependent trophism. <i>FASEB Journal</i> , 2019 , 33, 4703-4715	0.9	16
139	Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2021 , 268, 2379-2389	5.5	15
138	Monitoring retinal changes with optical coherence tomography predicts neuronal loss in experimental autoimmune encephalomyelitis. <i>Journal of Neuroinflammation</i> , 2019 , 16, 203	10.1	15
137	Thymic epithelium determines a spontaneous chronic neuritis in <i>Icam1(tm1Jcgr)</i> NOD mice. <i>Journal of Immunology</i> , 2014 , 193, 2678-90	5.3	15
136	FoxP3+ regulatory T cells determine disease severity in rodent models of inflammatory neuropathies. <i>PLoS ONE</i> , 2014 , 9, e108756	3.7	15
135	CXCR7 Is Involved in Human Oligodendroglial Precursor Cell Maturation. <i>PLoS ONE</i> , 2016 , 11, e0146503	3.7	15

134	Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	14
133	Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	14
132	A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol. <i>Journal of the Peripheral Nervous System</i> , 2018 , 23, 108-114	4.7	13
131	Contribution of spinal cord biopsy to diagnosis of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 882-8	5	13
130	Clinicogenomic factors of bioterapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020 , 17, e1003348	11.6	13
129	Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211024997	5	13
128	Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 17562864211039648	6.6	13
127	Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1776-1778	5	13
126	Dimethyl fumarate accelerates peripheral nerve regeneration via activation of the anti-inflammatory and cytoprotective Nrf2/HO-1 signaling pathway. <i>Acta Neuropathologica</i> , 2017 , 133, 489-491	14.3	12
125	Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 1092-1094	5.5	12
124	Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. <i>Journal of the Peripheral Nervous System</i> , 2019 , 24, 48-55	4.7	12
123	Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies. <i>Therapeutic Advances in Neurological Disorders</i> , 2016 , 9, 336-43	6.6	12
122	<i>Pseudomonas aeruginosa</i> and Its Bacterial Components Influence the Cytokine Response in Thymocytes and Splenocytes. <i>Infection and Immunity</i> , 2016 , 84, 1413-1423	3.7	12
121	IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties. <i>Trends in Pharmacological Sciences</i> , 2015 , 36, 419-21	13.2	12
120	Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	12
119	Monoclonal Antibodies for Multiple Sclerosis: An Update. <i>BioDrugs</i> , 2019 , 33, 61-78	7.9	12
118	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study. <i>Journal of the Peripheral Nervous System</i> , 2019 , 24, 72-79	4.7	11
117	Merits and culprits of immunotherapies for neurological diseases in times of COVID-19. <i>EBioMedicine</i> , 2020 , 56, 102822	8.8	11

116	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. <i>Neurology</i> , 2020 , 95, e1027-e1040	6.5	11
115	Immunoglobulins stimulate cultured Schwann cell maturation and promote their potential to induce axonal outgrowth. <i>Journal of Neuroinflammation</i> , 2015 , 12, 107	10.1	11
114	Managing Risks with Immune Therapies in Multiple Sclerosis. <i>Drug Safety</i> , 2019 , 42, 633-647	5.1	11
113	Alemtuzumab: Rare serious adverse events of a high-efficacy drug. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 737-740	5	11
112	Cryptococcal meningoencephalitis in an IgG-deficient patient with multiple sclerosis on fingolimod therapy for more than five years - case report. <i>BMC Neurology</i> , 2020 , 20, 158	3.1	10
111	Serum neurofilament light chain: No clear relation to cognition and neuropsychiatric symptoms in stable MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	10
110	Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review. <i>Journal of the Peripheral Nervous System</i> , 2020 , 25, 230-237	4.7	10
109	Oral Tolerance Induction in Experimental Autoimmune Encephalomyelitis with <i>Candida utilis</i> Expressing the Immunogenic MOG35-55 Peptide. <i>PLoS ONE</i> , 2016 , 11, e0155082	3.7	10
108	Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT. <i>Neurology</i> , 2020 , 94, e1950-e1960	6.5	10
107	Regulation of sirtuin expression in autoimmune neuroinflammation: Induction of SIRT1 in oligodendrocyte progenitor cells. <i>Neuroscience Letters</i> , 2019 , 704, 116-125	3.3	9
106	Axonal damage in papilledema linked to idiopathic intracranial hypertension as revealed by multifocal visual evoked potentials. <i>Clinical Neurophysiology</i> , 2015 , 126, 2040-1	4.3	9
105	Treatment of the First Acute Relapse Following Therapeutic Plasma Exchange in Formerly Glucocorticosteroid-Unresponsive Multiple Sclerosis Patients-A Multicenter Study to Evaluate Glucocorticosteroid Responsiveness. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	9
104	Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab. <i>BMC Neurology</i> , 2016 , 16, 98	3.1	9
103	Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond. <i>CNS Drugs</i> , 2018 , 32, 637-651	6.7	9
102	Moyamoya angiopathy: early postoperative course within 3 months after STA-MCA-bypass surgery in Europe-a retrospective analysis of 64 procedures. <i>Journal of Neurology</i> , 2018 , 265, 2370-2378	5.5	9
101	An unmet clinical need: roads to remyelination in MS. <i>Neurological Research and Practice</i> , 2019 , 1, 21	3.2	9
100	Advances in the management of multiple sclerosis-related spasticity. <i>Expert Review of Neurotherapeutics</i> , 2012 , 12, 1	4.3	9
99	Prolonged Neuropsychological Deficits, Central Nervous System Involvement, and Brain Stem Affection After COVID-19-A Case Series. <i>Frontiers in Neurology</i> , 2020 , 11, 574004	4.1	9

98	Activation of Wnt signaling promotes hippocampal neurogenesis in experimental autoimmune encephalomyelitis. <i>Molecular Neurodegeneration</i> , 2016 , 11, 53	19	9
97	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. <i>Journal of Neuroimmunology</i> , 2019 , 326, 19-27	3.5	9
96	Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study. <i>Journal of Neurology</i> , 2020 , 267, 308-316	5.5	9
95	Vaccination and multiple sclerosis in the era of the COVID-19 pandemic. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 1033-1043	5.5	9
94	Using Optical Coherence Tomography and Optokinetic Response As Structural and Functional Visual System Readouts in Mice and Rats. <i>Journal of Visualized Experiments</i> , 2019 ,	1.6	8
93	Whole-body positional manipulators for ocular imaging of anaesthetised mice and rats: a do-it-yourself guide. <i>BMJ Open Ophthalmology</i> , 2017 , 1, e000008	3.2	8
92	Cerebrospinal fluid findings in reversible cerebral vasoconstriction syndrome: a way to differentiate from cerebral vasculitis?. <i>Clinical and Experimental Immunology</i> , 2018 , 193, 341-345	6.2	8
91	Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data. <i>BMC Neurology</i> , 2019 , 19, 190	3.1	8
90	Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 46, 102492	4	8
89	Fampridine-PR (prolonged released 4-aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system. <i>Journal of the Peripheral Nervous System</i> , 2016 , 21, 85-97	4.7	8
88	Acetazolamide therapy in a case of fingolimod-associated macular edema: early benefits and long-term limitations. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 406-408	4	7
87	Old and new breakthroughs in neuromyelitis optica. <i>Lancet Neurology</i> , 2020 , 19, 280-281	24.1	7
86	Infectious risk stratification in multiple sclerosis patients receiving immunotherapy. <i>Annals of Clinical and Translational Neurology</i> , 2017 , 4, 909-914	5.3	7
85	Identification of novel myelin repair drugs by modulation of oligodendroglial differentiation competence. <i>EBioMedicine</i> , 2021 , 65, 103276	8.8	7
84	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	7
83	Clinical trials in multiple sclerosis: potential future trial designs. <i>Therapeutic Advances in Neurological Disorders</i> , 2019 , 12, 1756286419847095	6.6	6
82	Drug Treatment of Clinically Isolated Syndrome. <i>CNS Drugs</i> , 2019 , 33, 659-676	6.7	6
81	Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta. <i>Frontiers in Neurology</i> , 2017 , 8, 305	4.1	6

80	Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis. <i>Expert Review of Clinical Pharmacology</i> , 2012 , 5, 649-65	3.8	6
79	Novel treatment for immune neuropathies on the horizon. <i>Journal of the Peripheral Nervous System</i> , 2011 , 16, 75-83	4.7	6
78	The pentapeptide QYNAD does not inhibit neuronal network activity. <i>Canadian Journal of Neurological Sciences</i> , 2005 , 32, 344-8	1	6
77	Disability Outcomes in the N-MOMentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	6
76	Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis. <i>Current Opinion in Neurology</i> , 2021 , 34, 598-603	7.1	6
75	Meningitis gone viral: description of the echovirus wave 2013 in Germany. <i>BMC Infectious Diseases</i> , 2019 , 19, 1010	4	6
74	Case of alopecia universalis associated with alemtuzumab treatment in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018 , 5, e454	9.1	5
73	Consequences of COVID-19 pandemic lockdown on emergency and stroke care in a German tertiary stroke center. <i>Neurological Research and Practice</i> , 2021 , 3, 21	3.2	5
72	Association of Retinal Layer Thickness With Cognition in Patients With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	5
71	Redox Events As Modulators of Pathology and Therapy of Neuroinflammatory Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2016 , 4, 63	5.7	5
70	Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study. <i>European Journal of Neurology</i> , 2020 , 27, 196-203	6	5
69	Late age onset of amyotrophic lateral sclerosis is often not considered in elderly people. <i>Acta Neurologica Scandinavica</i> , 2018 , 137, 329-334	3.8	5
68	Prehistoric enemies within: The contribution of human endogenous retroviruses to neurological diseases. Meeting report: "Second International Workshop on Human Endogenous Retroviruses and Disease", Washington DC, March 13th and 14th 2017. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 15, 18-23	4	4
67	Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. <i>Journal of Neurology</i> , 2015 , 262, 2466-71	5.5	4
66	ECTRIMS/ACTRIMS 2017: Closing in on neurorepair in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 696-700	5	4
65	Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 36, 101335	4	4
64	Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases. <i>Acta Neurologica Scandinavica</i> , 2019 , 140, 290-295	3.8	4
63	Volume transmission-mediated encephalopathies: a possible new concept?. <i>Archives of Neurology</i> , 2012 , 69, 315-21		4

62	Neurological manifestations of severe acute respiratory syndrome coronavirus 2-a controversy gone viral? <i>Brain Communications</i> , 2020 , 2, fcaa149	4.5	4
61	Comparison of different optomotor response readouts for visual testing in experimental autoimmune encephalomyelitis-optic neuritis. <i>Journal of Neuroinflammation</i> , 2020 , 17, 216	10.1	4
60	Neuroprotective Properties of 4-Aminopyridine. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	4
59	Corneal confocal microscopy differentiates inflammatory from diabetic neuropathy. <i>Journal of Neuroinflammation</i> , 2021 , 18, 89	10.1	4
58	Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 49, 102695	4	4
57	Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 565-573	5	4
56	Long-term adherence and response to botulinum toxin in different indications. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 15-28	5.3	4
55	Sensitivity analysis of the primary endpoint from the N-MOMentum study of inebilizumab in NMOSD. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 2052-2061	5	4
54	The dark side of the moon: looking beyond beneficial effects of cannabis use in multiple sclerosis. <i>Brain</i> , 2019 , 142, 2552-2555	11.2	3
53	Interferon Beta for multiple sclerosis: old drug, new clothes. <i>Lancet Neurology</i> , 2014 , 13, 638-9	24.1	3
52	Predicting the Response to Intravenous Immunoglobulins in an Animal Model of Chronic Neuritis. <i>PLoS ONE</i> , 2016 , 11, e0164099	3.7	3
51	Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology. <i>CNS Drugs</i> , 2021 , 35, 1173-1188	6.7	3
50	Heterogeneous fate choice of genetically modulated adult neural stem cells in gray and white matter of the central nervous system. <i>Glia</i> , 2020 , 68, 393-406	9	3
49	Corneal Confocal Microscopy Demonstrates Corneal Nerve Loss in Patients With Trigeminal Neuralgia. <i>Frontiers in Neurology</i> , 2020 , 11, 661	4.1	3
48	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 48, 102673	4	3
47	Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets. <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 17562864211019598	6.6	3
46	Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	3
45	Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management.. <i>Neurotherapeutics</i> , 2022 , 1	6.4	3

44	Vaccination and immunotherapies in neuroimmunological diseases.. <i>Nature Reviews Neurology</i> , 2022 ,	15	3
43	CSI: Multiple sclerosis. Tracing optic nerve involvement by standardized optical coherence tomography. <i>Annals of Neurology</i> , 2019 , 85, 615-617	9.4	2
42	No Alteration of Optical Coherence Tomography and Multifocal Visual Evoked Potentials in Eyes With Symptomatic Carotid Artery Disease. <i>Frontiers in Neurology</i> , 2019 , 10, 741	4.1	2
41	Fulminant intramedullary spinal cord sarcoidosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 18, 47-48	4	2
40	Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy.. <i>Brain</i> , 2022 ,	11.2	2
39	CSF Findings in Acute NMDAR and LGI1 Antibody-Associated Autoimmune Encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	2
38	AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 57, 103356	4	2
37	Case Report: A Case of Severe Clinical Deterioration in a Patient With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020 , 11, 782	4.1	2
36	Vestibular hypofunction after monosodium glutamate ingestion: broadening the spectrum of Chinese restaurant syndrome? <i>Journal of Neurology</i> , 2016 , 263, 1027-1028	5.5	2
35	The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 479-482	5	2
34	Neuroprotective Properties of Dimethyl Fumarate Measured by Optical Coherence Tomography in Non-inflammatory Animal Models. <i>Frontiers in Neurology</i> , 2020 , 11, 601628	4.1	2
33	The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies.. <i>Neurotherapeutics</i> , 2022 , 1	6.4	2
32	Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022 ,	5.5	2
31	Retinal Changes After Posterior Cerebral Artery Infarctions Display Different Patterns of the Nasal and Temporal Sector in a Case Series. <i>Frontiers in Neurology</i> , 2020 , 11, 508	4.1	1
30	Capillary microscopy in Europeans with idiopathic Moyamoya angiopathy. <i>Microcirculation</i> , 2020 , 27, e12616	2.9	1
29	Acute exacerbations after decades of non-active chronic multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1265-1266	5	1
28	Immune mechanisms in neurological disease 2002 , 1501-1526		1
27	Suppression of P2-T-cell line mediated experimental autoimmune neuritis by interleukin-2 receptor blockade. <i>Annals of the New York Academy of Sciences</i> , 1988 , 540, 563-5	6.5	1

26	CNS Involvement in Chronic Inflammatory Demyelinating Polyneuropathy: Subtle Retinal Changes in Optical Coherence Tomography. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	1
25	Body mass index as a predictor of MS activity and progression among participants in BENEFIT.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211061861	5	1
24	Relapse-independent multiple sclerosis progression under natalizumab. <i>Brain Communications</i> , 2021 , 3, fcab229	4.5	1
23	NK cell markers predict the efficacy of IV immunoglobulins in CIDP. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	1
22	Retinal layers and visual conductivity changes in a case series of microangiopathic ischemic stroke patients. <i>BMC Neurology</i> , 2020 , 20, 333	3.1	1
21	Type O blood group associates with higher anti-JC polyomavirus antibody levels. <i>Brain and Behavior</i> , 2021 , 11, e2298	3.4	1
20	Meeting report: "Human endogenous retroviruses: HERVs or transposable elements in autoimmune, chronic inflammatory and degenerative diseases or cancer", Lyon, France, november 5th and 6th 2019 - an MS scientist's digest. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 42, 102068	4	1
19	Electrophysiological testing in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin: The Polyneuropathy And Treatment with Hizentra (PATH) study. <i>Clinical Neurophysiology</i> , 2021 , 132, 226-231	4.3	1
18	Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021 , 10, 839-850	4.5	1
17	Eculizumab versus rituximab in generalised myasthenia gravis.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022 ,	5.5	1
16	The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.. <i>Journal of Neurology</i> , 2022 , 1	5.5	1
15	4-Aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect - Commentary. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1312-1314	5	0
14	Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.. <i>Journal of Neurology</i> , 2022 , 1	5.5	0
13	Semi-Automated Live Tracking of Microglial Activation in CX3CR1 Mice During Experimental Autoimmune Encephalomyelitis by Confocal Scanning Laser Ophthalmoscopy. <i>Frontiers in Immunology</i> , 2021 , 12, 761776	8.4	0
12	Microglia contributes to remyelination in cerebral but not spinal cord ischemia. <i>Glia</i> , 2021 , 69, 2739-2751		0
11	Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. <i>Clinical Neurophysiology</i> , 2021 , 132, 2184-2190	4.3	0
10	Tissue donations for multiple sclerosis research: current state and suggestions for improvement.. <i>Brain Communications</i> , 2022 , 4, fcac094	4.5	0
9	Coronary angiography as a rare cause for incomplete anterior spinal artery syndrome. <i>Journal of Neurology</i> , 2017 , 264, 799-801	5.5	

- 8 Plasma exchange: are bigger studies necessarily better?. *Nature Reviews Neurology*, **2012**, 8, 410-410 15
- 7 G15 Switch of cerebral A1 adenosine receptor radioligand binding during phenoconversion of Huntington disease: a PET study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2012**, 83, A31.1-A31 5.5
- 6 Adoptive transfer experimental autoimmune encephalomyelitis. Evidence for central nerve and spinal root dysfunction. *Annals of the New York Academy of Sciences*, **1988**, 540, 738-40 6.5
- 5 Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population.. *Frontiers in Immunology*, **2021**, 12, 794075 8.4
- 4 Neuromyelitis Optica Spectrum Disorder: Therapeutic Innovations and Complex Decision-Making. *Annals of Neurology*, **2021**, 89, 1084-1087 9.4
- 3 Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk. *Neurotherapeutics*, **2021**, 18, 1654-1656 6.4
- 2 Analysis of Relapse by Inflammatory Rasch-built Overall Disability Scale Status in the PATH Study of Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy.. *Journal of the Peripheral Nervous System*, **2022**, 4.7
- 1 031 Long-term efficacy of ocrelizumab in primary progressive multiple sclerosis: 6.5-study years. *Journal of Neurology, Neurosurgery and Psychiatry*, **2022**, 93, A23.1-A23 5.5